Pharmaceutical company Starpharma is to establish a new UK based company called Petalion Therapeutics Limited in joint venture with life sciences investment firm Medicxi,. Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies in oncology, utilising Starpharma’s proprietary DEP dendrimer platform technology. Medicxi will fund Petalion with an initial investment of up to…
A federal government science grant and industry funding has sparked the creation of a new research and industry hub targeting the development of new radiopharmaceuticals. Pharmaceutical developer Starpharma has partnered with the University of Queensland and the University of Sydney in establishing the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub). Backed…
Starpharma’s Viraleze antiviral nasal spray has passed another trial confirming its effectiveness – this time showing it provides protection against infection with the highly transmissible SARS-CoV-2 Omicron variant of the virus which causes Covid-19. One hundred per cent of animals treated with Viraleze in a viral challenge test by Scripps Research had no detectable virus…
By Peter Roberts I have nothing but the deepest respect for Australia’s Therapeutic Goods Administration, but a certain lack of initiative on the part of the TGA seems to be preventing Australians from getting access to the latest Australian-developed tools to fight Covid-19. Make no mistake the TGA has an exemplary record in regulating Australians’…
Pharmaceutical developer Starpharma has reported its strong financial position and progress on numerous R&D fronts over the March quarter as it accelerates research and commercialisation of its drug portfolio. The Melbourne company spent $4.3 million on R&D in the quarter as well as manufacturing expenses, ending with a closing cash balance of $64.3 million. Net…
Pharmaceutical developer Starpharma has secured United Kingdom distribution for its Viraleze antiviral nasal spray. The Melbourne company has signed a sales and distribution agreement with LloydsPharmacy which operates 1,400 pharmacy stores in the UK and is part of international pharma distributor group McKesson. McKesson supplies more than 14,000 pharmacies across the UK. Viraleze spray, which…
Orbital expects new drone engine model production in FY24 Drone engine manufacturer Orbital Corporation (Orbital UAV) has reported a fall in revenues in athe first half of FY24 however directors revealed a new engine model could be manufactured as early as April, 2024. The Perth company reported a net loss of $425,000, down 76 percent…
a2 Milk Company grows despite decline in China market The a2 Milk Company, which pioneered the use of a2 proteins in milk as a healthy alternative, has reported positive results for 1H24. Revenue was up 3.7 percent to $812.1 million and EBITDA profit up five percent to $113.2 million despite a double-digit decline in the…
Viraleze shows efficacy in Covid-19 patients – Starpharma Starpharma’s Viraleze antiviral nasal spray has demonstrated antiviral efficacy in a placebo-controlled study in participants with Covid-19. Viraleze achieved a statistically significant reduction in SARS-CoV-2 viral load, in the cohort of participants aged 45 and over. Viral load in the nose was reduced by 80 percent less…
Iluka reveals capital cost of rare earths refinery Perth minerals company Iluka Resources has revealed a $1.5 to $1.8 billion capital cost of Australia’s first integrated rare earths refinery for producing rare earths oxides at Eneabba in Western Australia. The estimate comes from Iluka and Fluor who are optimising the project and conducting FEED work.…
